An innovative urinary drainage system that could reduce NHS CAUTI treatment costs by 10% and increase quality-of-life for men suffering from chronic incontinence

Ingenion是一家总部位于英国的医疗器械中小企业，其核心项目团队由Edward Cappabianca(项目负责人)、Susan Finch(项目经理)、James Barnett(设计工程师)、Tim Maloney(商务总监)和Zia Mursalen(财务经理)组成。尿失禁影响身体和心理健康，导致羞辱和社会问题。频繁的导尿增加了导管相关性尿路感染(CAUTIs)的风险，这可能是致命的，并导致NHS GB 567.6M/年的费用。CAUTIs占所有卫生保健相关感染(HCAIs)的17.2%，据估计，HCAIs给NHS造成的成本在1.6-5B GB/年之间(加拿大-感染杂志-控制，2020年9月)。长期使用导管的人平均每年经历2.7次CAUTIs(Colopast，2023)，每次事件的成本为3,500 GB。英国约有9万人使用长期导尿管，全球每年使用的导尿管超过4B。一些人试图通过少喝水来控制尿失禁，但事实证明，这会加剧明显无关的疾病，如痴呆症。为了解决这一未得到满足的需求，Ingenion正在开发一种革命性的留置尿液引流系统(_**Cym**Active_SealSoft)，该系统不需要外部袋子或管子。_**Cym**Active_SealSoft失禁设备将为男性患者提供正常的充盈/排空周期，没有任何不便或CAUTis风险。这一创新将对患有多发性硬化症、帕金森氏症、脊髓损伤和脊柱裂的患者产生重大影响。这不仅会提高他们的生活质量，而且还会让他们保持活跃，从而延长他们的预期寿命。该设备的独特卖点是其防泄漏设计和获得专利的磁阀技术，这确保了更大的信心和潜在的经济效益，因为NHS的CAUTI治疗成本降低了10%与CAUTI相关的HCAI可能高达57M/年。

Ingenion is a UK-based medical device SME with a core project team of Edward Cappabianca (project lead), Susan Finch (project manager), James Barnett (design engineer), Tim Maloney (commercial director) and Zia Mursaleen (finance manager).Urinary incontinence impacts physical and emotional health, causing humiliation and social issues. Frequent catheterisation increases the risk of catheter-associated urinary tract infections (CAUTIs), which can be fatal and cost the NHS £567.6M/year. CAUTIs represent 17.2% of all Health-Care Associated Infections (HCAIs), and HCAIs have been estimated to cost the NHS between £1.6-£5B/year (Canadian-Journal-of -Infection-Control,Sep2020). Long-term catheter users experience an average of 2.7 CAUTIs per year (Coloplast, 2023), with a cost of £3,500 per incident. Around 90,000 people in the UK live with long-term catheters, with over 4B catheters used worldwide annually. Some people try to manage incontinence by drinking less water, but this has been shown to worsen apparently unrelated conditions, such as dementia.To solve this unmet need, Ingenion is developing a revolutionary indwelling urinary drainage system (_**cym**active_ SealSoft) that eliminates the need for external bags or tubes. The _**cym**active_ SealSoft device for incontinence will provide male patients with normal fill/void cycles without any inconvenience or risk of CAUTIs.This innovation will have a significant impact on patients suffering from MS, Parkinson's, spinal cord injuries and spina bifida. Not only will it improve their quality of life, but it will also help increase their life expectancy by allowing them to remain active. The unique selling points of this device are its leak-proof design and patented magnetic valve technology, which ensures greater confidence and a potential economic benefit from a reduction in CAUTI treatment costs for the NHS by 10% of the HCAIs related to CAUTIs could be as much as £57M/year.